title: Serum opsonins to serogroup B meningococci after disease and vaccination.
abstract: In this review the results of three previous studies are compared and discussed. Sera from 101 patients with meningococcal disease and from 113 volunteers immunized twice with vaccine preparations against serogroup B meningococci were examined for antimeningococcal opsonic activity using a chemiluminescence (CL) method. Twelve groups of vaccinees were immunized twice with one of four different doses of an outer membrane vesicle (OMV) preparation either alone or complexed to serogroup C polysaccharide and/or the adjuvant Al(OH)3. The OMV vaccine strain (44/76) was a patient isolate characterized as B:15:P1.16. The 89 surviving patients and 97/113 volunteers responded with significantly increased opsonic activity to the vaccine strain. Sera from all vaccinees with low preimmunization levels demonstrated a significant postimmunization increase in opsonic activity. The vaccine response was dose related, and the second injection induced a booster response in those who received preparations containing Al(OH)3. At 26 weeks a reduction in opsonic activity to preimmunization levels was noted in 19/97 previous responders. The reduction was less pronounced in those who were immunized with the higher doses. Using CL and flow cytometry we found vaccinee sera to show cross reacting opsonin responses to other serogroups and serotypes of meningococci except meningococci of serotype 2a and 2b. The increase in antimeningococcal opsonins after vaccination suggests that the serogroup B OMV vaccine may induce protection against clinical disease.
authors.affiliation: Medical Department B, University of Bergen, Haukeland Hospital.
authors.forename: A
authors.initials: A
authors.lastname: Halstensen
authors.forename: A K
authors.initials: AK
authors.lastname: Lehmann
authors.forename: H K
authors.initials: HK
authors.lastname: Guttormsen
authors.forename: S E
authors.initials: SE
authors.lastname: Vollset
authors.forename: G
authors.initials: G
authors.lastname: Bjune
authors.forename: A
authors.initials: A
authors.lastname: Naess
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016667:Bacterial Capsules; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003429:Cross Reactions; D004306:Dose-Response Relationship, Immunologic; D005069:Evaluation Studies as Topic; D005434:Flow Cytometry; D006801:Humans; D007223:Infant; D008163:Luminescent Measurements; D008589:Meningococcal Infections / Q000097:blood / Q000276:immunology* / Q000382:microbiology; D022401:Meningococcal Vaccines; D008875:Middle Aged; D009895:Opsonin Proteins / Q000097:blood* / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D012703:Serotyping; D013997:Time Factors
chemical_list: D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D009895:Opsonin Proteins; D011135:Polysaccharides, Bacterial; C039455:capsular polysaccharide, meningococcal group B